Publications

Cell cycle (Georgetown, Tex.)

Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.

01-09-2008

Current biology : CB

Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium.

22-07-2008

Clinical cancer research : an official journal of the American Association for Cancer Research

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

15-06-2008

Cell

Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks.

16-05-2008

Cell cycle (Georgetown, Tex.)

How do real tumors become resistant to cisplatin?

15-05-2008

Nucleic acids research

Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data.

01-02-2008

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Modeling therapy resistance in genetically engineered mouse cancer models.

01-01-2008

Cell cycle (Georgetown, Tex.)

What makes tumors multidrug resistant?

15-11-2007

Physiol Genomics: Physiological genomics

Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues

19-09-2007

Journal of mammary gland biology and neoplasia

Modeling metastatic breast cancer in mice.

01-09-2007

Proceedings of the National Academy of Sciences of the United States of America

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

17-07-2007

Proceedings of the National Academy of Sciences of the United States of America

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.

17-07-2007

Nature genetics

MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.

01-06-2007

Cancer research

Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage

15-05-2007

Gastroenterology

Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease

01-04-2007

Cell

Further evidence for BRCA1 communication with the inactive X chromosome

09-03-2007

Am J Pathol: The American journal of pathology

Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human

01-01-2007

Experimental cel research

Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes

01-01-2007

Cancer cell

Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.

01-11-2006

Oncogene

Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.

25-09-2006

Molecular and cellular biology

Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.

01-07-2006

FASEB journal: official publication of the Federation of American Societies for Experimental Biology

Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice

01-05-2006

Nucleic acids research

Human and mouse oligonucleotide-based array CGH

16-12-2005

Cancer research

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development

15-09-2005

Genes & development

Frat is dispensable for canonical Wnt signaling in mammals.

15-02-2005

Cancer cell

Oncogene addiction: sometimes a temporary slavery.

01-12-2004

Oncogene

Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas.

12-08-2004

Nature genetics

Mutagenic insertion and chromosome engineering resource (MICER)

01-08-2004

Molecular and cellular biology

Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.

01-07-2004

The Journal of biological chemistry

Characterization and functional analysis of the murine Frat2 gene.

25-06-2004

Genome research

A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization

01-01-2004

Nature reviews. Cancer

Conditional mouse models of sporadic cancer.

01-04-2002

Cancer research

Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice.

15-03-2002

Nature genetics

Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

01-12-2001

Proceedings of the National Academy of Sciences of the United States of America

Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells.

31-07-2001

EMBO reports

A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent.

01-04-2001

Experimental cell research

Mouse models for sporadic cancer.

10-03-2001

Cancer gene therapy

Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome

01-10-2000

Genes & development

Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum.

15-04-2000

Mechanisms of development

In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3.

01-11-1999

Oncogene

Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression.

28-10-1999

The EMBO journal

Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1

02-08-1999

Cancer research

Identification and characterization of collaborating oncogenes in compound mutant mice.

01-04-1999

The EMBO journal

Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas.

03-02-1997

Journal of virology

Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pim-1 transgenic mice.

01-01-1997

Biochimica et biophysica acta

Retroviral insertional mutagenesis as a strategy to identify cancer genes.

16-05-1996

Cold Spring Harbor symposia on quantitative biology

Mouse model systems to study multistep tumorigenesis.

01-01-1994

Plant molecular biology

Preparation of megabase-sized tomato DNA and separation of large restriction fragments by field inversion gel electrophoresis (FIGE)

01-03-1989

Oncotarget

Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells

01-01-0001

Breast Cancer Research: BCR

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression

01-01-0001

Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.

Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium.

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks.

How do real tumors become resistant to cisplatin?

Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data.

Modeling therapy resistance in genetically engineered mouse cancer models.

What makes tumors multidrug resistant?

Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues

Modeling metastatic breast cancer in mice.

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.

MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.

Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage

Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease

Further evidence for BRCA1 communication with the inactive X chromosome

Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human

Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes

Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.

Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.

Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.

Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice

Human and mouse oligonucleotide-based array CGH

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development

Frat is dispensable for canonical Wnt signaling in mammals.

Oncogene addiction: sometimes a temporary slavery.

Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas.

Mutagenic insertion and chromosome engineering resource (MICER)

Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.

Characterization and functional analysis of the murine Frat2 gene.

A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization

Conditional mouse models of sporadic cancer.

Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice.

Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells.

A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent.

Mouse models for sporadic cancer.

Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome

Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum.

In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3.

Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression.

Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1

Identification and characterization of collaborating oncogenes in compound mutant mice.

Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas.

Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pim-1 transgenic mice.

Retroviral insertional mutagenesis as a strategy to identify cancer genes.

Mouse model systems to study multistep tumorigenesis.

Preparation of megabase-sized tomato DNA and separation of large restriction fragments by field inversion gel electrophoresis (FIGE)

Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression

This site uses cookies